China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its pipeline candidate ZG005. The Category 1 biologic product will be tested in combination with a platinum-containing chemotherapy regimen for advanced biliary tract cancer.
Drug Profile
ZG005 is a bispecific antibody (BsAb) targeting programmed-death 1 (PD-1) and T-cell immunoreceptor with Ig and ITIM domains (TIGIT). The drug is designed to treat multiple solid tumors and is the first of its kind to enter clinical trials globally.
Clinical Trial
The upcoming trial will evaluate ZG005’s efficacy and safety in patients with advanced biliary tract cancer. The lack of similar approved products highlights the potential of ZG005 to fill an unmet medical need.-Fineline Info & Tech
